Home – Neurimmune

Committed to promote independence in life

by pioneering novel treatments

NI101SQ is a novel subcutaneous version of aducanumab, formulated for autoinjector self-administration. It is a human monoclonal antibody against beta amyloid in development for the treatment of Alzheimer's disease.

NI101SQ

Transforming the wisdom of life

into promising drug candidates

Besides aducanumab, Neurimmune’s scientists discovered with the Reverse Translational Medicine technology the anti-SOD1 antibody AP-101 for amyotrophic lateral sclerosis and the anti-ATTR antibody NI006 for ATTR cardiomyopathy. These programs are currently evaluated in clinical trials.

Neurimmune pipeline

Decoding immune memories of life

to develop therapeutic antibodies

By using Reverse Translational Medicine™ technology, Neurimmune’s scientists and researchers translate genetic information of lymphocyte transcripts from elderly human donors into therapeutic antibodies. Evolutionarily optimized and wisely elected antibodies with preferred activities combine high affinity with target selectivity, excellent pharmacodynamics and low immunogenicity.

RTM™ Technology Platform

Scientific publications

View all

N Engl J Med - 2023

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Sci Transl Med. - 2018

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis

Nature - 2016

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

News

View all

23.10.2024 | Company News

Neurimmune today announced that the translational PK/PD model relating to the human antibody ALXN2220 (formerly NI006) have been published in the current issue of Clinical Pharmacology & Therapeutics.

14.10.2024 | Company News

Neurimmune today announced that the U.S. Food and Drug Administration has granted Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 (formerly NI006) for the treatment of transthyretin amyloidosis with cardiomyopathy.

27.08.2024 | Company News

Neurimmune today announced that long-term safety and efficacy data from the open-label extension of a Phase I trial related to ALXN2220 will be presented in London at the ESC Congress 2024.

Driven by the passion for life

to help patients around the world

Roger M Nitsch, MD

CEO

View details

Christoph Hock, MD

CMO

View details

Jan Grimm, PhD

CSO

View details